Clik here to view.
Diabetes: Senseonics raises $20M for continuous glucose monitoring implant
UPDATED June 5, 2014, with new round total and comment from Senseonics. Senseonics said it raised $20 million it plans to put toward pivotal trials of its fully implantable blood glucose monitor for...
View ArticleClik here to view.
Senseonics gains funding for continuous glucose monitoring implant | Medtech...
Diabetes: Senseonics raises $20M for continuous glucose monitoring implant June 5, 2014 by Arezu Sarvestani Senseonics said it raised $20 million it plans to put toward pivotal trials of its fully...
View ArticleClik here to view.
Amniox Medical taps ex-Smith & Nephew honcho Dugan for CEO | Personnel Moves
Amniox Medical said it named former Smith & Nephew (FTSE:SN, NYSE:SNN) executive Thomas Dugan as its new CEO. Amniox, a subsidiary of TissueTech, makes amniotic membrane- and umbilical cord-based...
View ArticleClik here to view.
Senseonics raises $10m for implanted glucose sensor
Implantable glucose monitor developer Senseonics raised $10 million in a new round of equity financing, according to an SEC filing. Senseonics is developing micro-sized sensors and connected smartphone...
View ArticleClik here to view.
Senseonics implantable CGM pivotal meets interim endpoint
Senseonics said today a clinical study of its implantable, long-term continuous glucose monitoring system met its interim phase primary effectiveness and safety endpoints. Senseonics is developing...
View ArticleClik here to view.
Senseonics closes ASN Tech merger
Senseonics said today it closed its merger with ASN Technologies. As part of the buy, ASN Technologies changed its name to Senseonics Holdings and “disposed” of its legacy business through selling...
View ArticleClik here to view.
Senseonics registers for $52m IPO
Senseonics yesterday registered for an initial public offering worth up to $51.8 million as it gears up to get its Eversense implantable continuous glucose monitor on the market. Germantown, Md.-based...
View ArticleClik here to view.
Diabetes: Senseonics launches pivotal of 90-day implantable glucose monitor
Senseonics said today it launched the Precise II trial of its Eversense fully implantable, long-term continuous glucose monitor for individuals suffering from diabetes. The Eversense monitor uses a...
View ArticleClik here to view.
Senseonics partners with Diasend for analysis of CGM data
Senseonics said yesterday it inked a collaborative deal with Diasend to use its diasend Clinic and diasend Personal solutions to analyze data from Senseonics Eversense continuous glucose monitoring...
View ArticleClik here to view.
Senseonics sets terms for $64m offering
Senseonics (OTC:SENH) set the terms today on a public stock offering that could fetch nearly $64 million, as the implantable glucose monitor maker looks to move to the New York Stock Exchange....
View ArticleClik here to view.
Report: U.S. IPOs hit 7-year low during 2016 1st quarter
The U.S. market for initial public offerings hit its lowest mark during the 1st quarter since the financial crisis hit in 2008 and 2009 and every flotation was for a healthcare company, according to a...
View ArticleClik here to view.
Senseonics wins CE Mark for implantable CGM system
Senseonics (OTC:SENH) said today it won CE Mark approval in the European Union for its Eversense continuous glucose monitoring system. The Eversense system includes an implanted glucose sensor designed...
View ArticleClik here to view.
Senseonics inks exclusive Eversense CGM EU distro deal with Roche
Senseonics (OTC:SENH) said today it inked an exclusive distribution agreement with Roche (PINK:RHHBY) for the multi-country commercialization of the Eversense continuous glucose monitor. Under the...
View ArticleClik here to view.
Senseonics takes out $30m term loan
Senseonics (NYSE:SENS) said yesterday that it took out a term loan worth $30 million from Oxford Finance and Silicon Valley Bank, augmenting the $45 million it raised in an initial public offering in...
View ArticleClik here to view.
Senseonics submits FDA PMA application for Eversense CGM
Senseonics (NYSE:SENS) said today it submitted a premarket approval application to the FDA for its Eversense continuous glucose monitoring system. The Eversense system includes an implanted glucose...
View ArticleClik here to view.
Senseonics, Roche expand distribution deal for Eversense glucose monitor
Senseonics (NYSE:SENS) said today that it expanded its exclusive distribution agreement with Roche (PINK:RHHBY) for its implantable continuous glucose monitoring system for people with diabetes. The...
View ArticleClik here to view.
Senseonics prelim beat Q4 estimates
Senseonics (NYSE:SENS) saw shares rise 5.6% today after it released preliminary financial results for the 4th quarter, beating analysts’ expectations on Wall Street. The Germantown, Md.-based company...
View ArticleClik here to view.
Dexcom surges on Medicare nod for continuous glucose monitors
DexCom (NSDQ:DXCM) said yesterday that the Centers for Medicare & Medicaid classified therapeutic continuous glucose monitors as durable medical equipment under Medicare Part B. The company’s...
View ArticleClik here to view.
RTI Surgical names new CEO, parts ways with CSO Hartill | Personnel Moves,...
RTI Surgical (NSDQ:RTIX) named Camille Farhat as its chief executive officer, effective March 15, 2017. Previously, Farhat served as president & CEO of American Medical Systems, Inc., where he...
View ArticleClik here to view.
Senseonics draws 3rd $5m tranche for implantable CGM
Senseonics (NYSE:SENS) said last month that it drew the 3rd installment of $5 million under its term loan facility with Oxford Finance and Silicon Valley Bank. The 3rd tranche, which closed on March 29...
View Article